We are narrowing the genomic data disparity gap with our robust health information ecosystem, which consists of the 54gene Biobank consisting of highly curated clinical, phenotypic and genetic data. This platform generates insights to solve global healthcare challenges.
Partners with a mutual interest in drug discovery are increasingly requiring data cohorts that cover diverse populations to undertake novel research, enhance disease understanding, and make new discoveries.
To discover effective therapeutic targets for debilitating diseases with little to no cures, new biological insights derived from studying diverse genomes must be uncovered.
The 54gene Biobank, our state-of-the-art biorepository which stores samples and the accompanying clinical, phenotypic and genetic data in optimum conditions to enable insight generation for a new wave of therapeutics.
Our extensive reach to unique data sets, best-in-class equipment, state-of-the-art laboratories and expert in-house capabilities drive us towards our goal to equalise precision medicine globally.
Our clinical and research teams are committed to using our vast genetic database to support the development of therapeutics including drugs and vaccines for non-communicable and communicable diseases, for both academic and development research.
We are narrowing the genomic data disparity gap with our robust health information ecosystem, which consists of the 54gene Biobank consisting of highly curated clinical, phenotypic and genetic data. This platform generates insights to solve global healthcare challenges.
Undertake diverse research that allows companies to create products for global markets inclusive of African populations.
Utilize advanced Next Generation Sequencing and microarray services capable of supporting cutting-edge research and clinical programs.
Access rare variant data from diverse, previously inaccessible populations to advance their clinical programs and reduce time to market.
To keep up to date with events, services and initiatives, subscribe to our newsletter today.